Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
NCT ID: NCT03418038
Last Updated: 2025-07-16
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE2
Total Enrollment
80 participants
Study Classification
INTERVENTIONAL
Study Start Date
2018-03-23
Study Completion Date
2026-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined significance and chronic myelomonocytic leukemia (CMML). Ascorbic acid may make cancer cells more sensitive to chemotherapy. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ascorbic acid and combination chemotherapy may kill more cancer cells.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
NCT03136146
Recurrent Acute Lymphoblastic Leukemia
Recurrent Adult Lymphoblastic Lymphoma
Recurrent Burkitt Leukemia
+8 more
RECRUITING
PHASE2
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
NCT02213913
Adult Grade III Lymphomatoid Granulomatosis
B-cell Chronic Lymphocytic Leukemia
Contiguous Stage II Adult Diffuse Large Cell Lymphoma
+69 more
UNKNOWN
PHASE1/PHASE2
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
NCT00882206
Leukemia
Lymphoma
TERMINATED
PHASE2
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
NCT06210750
T Acute Lymphoblastic Leukemia
T Lymphoblastic Lymphoma
WITHDRAWN
PHASE2
Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
NCT02561273
Anaplastic Large Cell Lymphoma, ALK-Negative
Anaplastic Large Cell Lymphoma, ALK-Positive
Hepatosplenic T-Cell Lymphoma
+7 more
COMPLETED
PHASE1/PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PRIMARY OBJECTIVES:
I. To determine the overall response rate (ORR) at the end of 2 cycles for intravenous (IV) ascorbic acid (AA) added to standard salvage therapy compared to standard salvage therapy plus normal saline in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who have relapsed within the first 24 months of end of their therapy. \[Arms A versus (vs) B\] II. To determine the ORR at the end of 2 cycles of AA plus standard salvage chemotherapy in patients with other types of relapsed/refractory lymphomas not eligible for Arms A/B \[peripheral T-cell lymphoma (PTCL), double-hit high grade, and Hodgkin lymphoma (HL)\]. (Arm C) III. To assess the hematological response rate to treatment with high dose intravenous ascorbic acid (IV AA) for clonal cytopenia of undetermined significance (CCUS) patients. (Arm D) IV. To assess the hematological response rate to treatment with high dose intravenous ascorbic acid (IV AA) for CCUS patients. (Arm E)
SECONDARY OBJECTIVES:
I. To compare the adverse event profile of IV AA added to salvage therapy versus salvage therapy plus IV saline in patients with DLBCL using both the Common Terminology Criteria for Adverse Events (CTCAE) and Patient-Reported Outcomes (PRO)-CTCAE. (Arms A and B) II. To compare the progression-free survival, overall survival, clinical benefit rate (those not progressing), and percentage (%) transplant eligible patients proceeding to transplant of AA added to salvage therapy versus salvage therapy plus IV saline in patients with DLBCL. (Arms A and B) III. To compare the ORR at the end of 4 cycles for those with minor response/stable disease at the end of cycle 2 who proceed to receive the additional 2 cycles of rituximab, dexamethasone, cytarabine and cisplatin (RDHAP) with either AA or normal saline (NS) as previously assigned. (Arms A and B) IV. To evaluate the adverse event profile, rate of febrile neutropenia, overall survival, progression-free survival, and clinical benefit rate of AA added to salvage therapy in patients with relapsed/refractory lymphoma. (Arm C) V. To assess safety/tolerability, transfusion dependency (TD), progression-free survival (PFS), and overall survival (OS) for CCUS patients receiving high dose IV AA. (Arm D) VI. To define CR, complete cytogenetic remission, partial remission, marrow response, and clinical benefit response rates. (Arm E) VII. To determine clinical benefit response rates of erythroid response, platelet response, neutrophil response, spleen response and symptom response as adjudicated by the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) total symptom scoring system. (Arm E)
EXPLORATORY OBJECTIVES:
I. Will include baseline AA levels \[at Mayo Clinic Research (MCR)\] and staining of pre/post treatment biopsies for markers of oxidative stress generation and deoxyribonucleic acid (DNA) methylation. (Arms A, B, and C Correlative Research on blood and tumor tissue) IIa. To assess TET2 activity at baseline, weeks 12, 20, and 52. (Arm D correlative research) IIb. To assess the association between using AA and the hydroxymethylation and methylation status (gene-specific and global changes in 5mC/5hmC level) at baseline and weeks 20 and 52. (Arm D correlative research) IIc. To assess the association between using IV AA and endothelial dysfunction (at baseline, weeks 20, and 52). (Arm D correlative research) IId. To assess the association between using IV AA and the inflammation markers. (Arm D correlative research) IIe. To assess the association between using IV AA and molecular response including clonal dynamics \[new mutations and variant allele frequency (VAF)\] (at baseline, weeks 20, and 52). (Arm D correlative research)
III. Correlative studies will assess impact on:
IIIa. Somatic mutational allele burdens after 4 cycles of therapy; IIIb. DNA methylation and hydroxymethylation after 4 cycles of therapy; IIIc. Inflammatory cytokines; IIId. Colony forming assay growth and differentiation; IIIe. Methylation at the single colony level; IIIf. Single cell methylation, transcription, and somatic mutations. (Arm E correlative research)
OUTLINE: Patients with DLBCL are randomized to Arms A or B. Patients with other lymphomas are assigned to Arm C. Patients with CCUS are assigned to Arm D. Patients with TET2 mutant CMML are assigned to ARM E.
Arm A: Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19, and rituximab intravenously (IV), ifosfamide IV, carboplatin IV and etoposide IV on days 1-3. Patients who achieve minor response (MR) or stable disease (SD) after 2 cycles may receive rituximab IV or PO, cisplatin IV or PO, cytarabine IV or PO, and dexamethasone IV or PO. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
ARM B: Patients receive placebo (normal saline) IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19, and rituximab intravenously IV, ifosfamide IV, carboplatin IV and etoposide IV on days 1-3. Patients who achieve MR or SD after 2 cycles may receive rituximab IV or PO, cisplatin IV or PO, cytarabine IV or PO, and dexamethasone IV or PO. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
ARM C: Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19. Patients also receive ifosfamide, carboplatin, and etoposide IV or PO, or cisplatin, cytarabine, and dexamethasone IV or PO, or gemcitabine hydrochloride, dexamethasone, and cisplatin IV or PO, or gemcitabine hydrochloride and oxaliplatin IV or PO, or oxaliplatin, cytarabine, and dexamethasone IV or PO according to standard regimen schedule. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve MR or SD after 2 cycles may switch to an alternative chemotherapy regimen.
ARM D: Patients receive ascorbic acid IV three times a week (TIW). Treatments repeat every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
ARM E: Patients receive ascorbic acid IV on days 1, 3 and 5 and decitabine IV over 1 hour on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 12 cycles may continue decitabine with or without ascorbic acid as long as clinically appropriate. Patients may also take vitamin C PO on days 6-28.
In Arms A, B, and C, patients who achieve complete response (CR), partial response (PR) or MR may undergo stem cell transplantation. Patients additionally, undergo blood sample collection, core needle biopsy, bone marrow aspiration and biopsy, echocardiography (ECHO), positron emission tomography (PET)/ computed tomography (CT) or magnetic resonance imaging (MRI) throughout study.
Patients in ARM D and E undergo peripherally inserted central catheter (PICC) or portacath placement prior to starting treatment, blood sample collection, bone marrow aspiration and biopsy throughout study.
After completion of study treatment, patients are followed up every 3 months, then every 6 months after progressive disease for up to 2 years.
I. To determine the overall response rate (ORR) at the end of 2 cycles for intravenous (IV) ascorbic acid (AA) added to standard salvage therapy compared to standard salvage therapy plus normal saline in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who have relapsed within the first 24 months of end of their therapy. \[Arms A versus (vs) B\] II. To determine the ORR at the end of 2 cycles of AA plus standard salvage chemotherapy in patients with other types of relapsed/refractory lymphomas not eligible for Arms A/B \[peripheral T-cell lymphoma (PTCL), double-hit high grade, and Hodgkin lymphoma (HL)\]. (Arm C) III. To assess the hematological response rate to treatment with high dose intravenous ascorbic acid (IV AA) for clonal cytopenia of undetermined significance (CCUS) patients. (Arm D) IV. To assess the hematological response rate to treatment with high dose intravenous ascorbic acid (IV AA) for CCUS patients. (Arm E)
SECONDARY OBJECTIVES:
I. To compare the adverse event profile of IV AA added to salvage therapy versus salvage therapy plus IV saline in patients with DLBCL using both the Common Terminology Criteria for Adverse Events (CTCAE) and Patient-Reported Outcomes (PRO)-CTCAE. (Arms A and B) II. To compare the progression-free survival, overall survival, clinical benefit rate (those not progressing), and percentage (%) transplant eligible patients proceeding to transplant of AA added to salvage therapy versus salvage therapy plus IV saline in patients with DLBCL. (Arms A and B) III. To compare the ORR at the end of 4 cycles for those with minor response/stable disease at the end of cycle 2 who proceed to receive the additional 2 cycles of rituximab, dexamethasone, cytarabine and cisplatin (RDHAP) with either AA or normal saline (NS) as previously assigned. (Arms A and B) IV. To evaluate the adverse event profile, rate of febrile neutropenia, overall survival, progression-free survival, and clinical benefit rate of AA added to salvage therapy in patients with relapsed/refractory lymphoma. (Arm C) V. To assess safety/tolerability, transfusion dependency (TD), progression-free survival (PFS), and overall survival (OS) for CCUS patients receiving high dose IV AA. (Arm D) VI. To define CR, complete cytogenetic remission, partial remission, marrow response, and clinical benefit response rates. (Arm E) VII. To determine clinical benefit response rates of erythroid response, platelet response, neutrophil response, spleen response and symptom response as adjudicated by the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) total symptom scoring system. (Arm E)
EXPLORATORY OBJECTIVES:
I. Will include baseline AA levels \[at Mayo Clinic Research (MCR)\] and staining of pre/post treatment biopsies for markers of oxidative stress generation and deoxyribonucleic acid (DNA) methylation. (Arms A, B, and C Correlative Research on blood and tumor tissue) IIa. To assess TET2 activity at baseline, weeks 12, 20, and 52. (Arm D correlative research) IIb. To assess the association between using AA and the hydroxymethylation and methylation status (gene-specific and global changes in 5mC/5hmC level) at baseline and weeks 20 and 52. (Arm D correlative research) IIc. To assess the association between using IV AA and endothelial dysfunction (at baseline, weeks 20, and 52). (Arm D correlative research) IId. To assess the association between using IV AA and the inflammation markers. (Arm D correlative research) IIe. To assess the association between using IV AA and molecular response including clonal dynamics \[new mutations and variant allele frequency (VAF)\] (at baseline, weeks 20, and 52). (Arm D correlative research)
III. Correlative studies will assess impact on:
IIIa. Somatic mutational allele burdens after 4 cycles of therapy; IIIb. DNA methylation and hydroxymethylation after 4 cycles of therapy; IIIc. Inflammatory cytokines; IIId. Colony forming assay growth and differentiation; IIIe. Methylation at the single colony level; IIIf. Single cell methylation, transcription, and somatic mutations. (Arm E correlative research)
OUTLINE: Patients with DLBCL are randomized to Arms A or B. Patients with other lymphomas are assigned to Arm C. Patients with CCUS are assigned to Arm D. Patients with TET2 mutant CMML are assigned to ARM E.
Arm A: Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19, and rituximab intravenously (IV), ifosfamide IV, carboplatin IV and etoposide IV on days 1-3. Patients who achieve minor response (MR) or stable disease (SD) after 2 cycles may receive rituximab IV or PO, cisplatin IV or PO, cytarabine IV or PO, and dexamethasone IV or PO. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
ARM B: Patients receive placebo (normal saline) IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19, and rituximab intravenously IV, ifosfamide IV, carboplatin IV and etoposide IV on days 1-3. Patients who achieve MR or SD after 2 cycles may receive rituximab IV or PO, cisplatin IV or PO, cytarabine IV or PO, and dexamethasone IV or PO. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
ARM C: Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19. Patients also receive ifosfamide, carboplatin, and etoposide IV or PO, or cisplatin, cytarabine, and dexamethasone IV or PO, or gemcitabine hydrochloride, dexamethasone, and cisplatin IV or PO, or gemcitabine hydrochloride and oxaliplatin IV or PO, or oxaliplatin, cytarabine, and dexamethasone IV or PO according to standard regimen schedule. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve MR or SD after 2 cycles may switch to an alternative chemotherapy regimen.
ARM D: Patients receive ascorbic acid IV three times a week (TIW). Treatments repeat every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
ARM E: Patients receive ascorbic acid IV on days 1, 3 and 5 and decitabine IV over 1 hour on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 12 cycles may continue decitabine with or without ascorbic acid as long as clinically appropriate. Patients may also take vitamin C PO on days 6-28.
In Arms A, B, and C, patients who achieve complete response (CR), partial response (PR) or MR may undergo stem cell transplantation. Patients additionally, undergo blood sample collection, core needle biopsy, bone marrow aspiration and biopsy, echocardiography (ECHO), positron emission tomography (PET)/ computed tomography (CT) or magnetic resonance imaging (MRI) throughout study.
Patients in ARM D and E undergo peripherally inserted central catheter (PICC) or portacath placement prior to starting treatment, blood sample collection, bone marrow aspiration and biopsy throughout study.
After completion of study treatment, patients are followed up every 3 months, then every 6 months after progressive disease for up to 2 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Clonal Cytopenia of Undetermined Significance
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Hodgkin Lymphoma
Recurrent Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory Lymphoma
Chronic Myelomonocytic Leukemia
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
DOUBLE
Participants
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A (ascorbic acid, combination chemotherapy)
Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19, and rituximab intravenously IV, ifosfamide IV, carboplatin IV and etoposide IV on days 1-3. Patients who achieve MR or SD after 2 cycles may receive rituximab IV or PO, cisplatin IV or PO, cytarabine IV or PO, and dexamethasone IV or PO. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients additionally, undergo blood sample collection, core needle biopsy, bone marrow aspiration and biopsy, ECHO, PET/CT or MRI throughout study.
Group Type
EXPERIMENTAL
Ascorbic Acid
Intervention Type
DIETARY_SUPPLEMENT
Given IV
Carboplatin
Intervention Type
DRUG
Given IV or PO
Cisplatin
Intervention Type
DRUG
Given IV or PO
Cytarabine
Intervention Type
DRUG
Given IV or PO
Dexamethasone
Intervention Type
DRUG
Given IV or PO
Etoposide
Intervention Type
DRUG
Given IV or PO
Ifosfamide
Intervention Type
DRUG
Given IV or PO
Laboratory Biomarker Analysis
Intervention Type
OTHER
Correlative studies
Questionnaire Administration
Intervention Type
OTHER
Ancillary studies
Rituximab
Intervention Type
BIOLOGICAL
Given IV
Biospecimen Collection
Intervention Type
PROCEDURE
Undergo blood sample collection
Core Biopsy
Intervention Type
PROCEDURE
Undergo core needle biopsy
Bone Marrow Aspiration
Intervention Type
PROCEDURE
Undergo bone marrow aspiration and biopsy
Bone Marrow Biopsy
Intervention Type
PROCEDURE
Undergo bone marrow aspiration and biopsy
Echocardiography
Intervention Type
PROCEDURE
Undergo ECHO
Positron Emission Tomography
Intervention Type
PROCEDURE
Undergo PET/CT
Magnetic Resonance Imaging
Intervention Type
PROCEDURE
Undergo MRI
Computed Tomography
Intervention Type
PROCEDURE
Undergo PET/CT
Arm B (placebo, combination chemotherapy)
Patients receive placebo (normal saline) IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19, and rituximab intravenously IV, ifosfamide IV, carboplatin IV and etoposide IV on days 1-3. Patients who achieve MR or SD after 2 cycles may receive rituximab IV or PO, cisplatin IV or PO, cytarabine IV or PO, and dexamethasone IV or PO. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients additionally, undergo blood sample collection, core needle biopsy, bone marrow aspiration and biopsy, ECHO, PET/CT or MRI throughout study.
Group Type
ACTIVE_COMPARATOR
Carboplatin
Intervention Type
DRUG
Given IV or PO
Cisplatin
Intervention Type
DRUG
Given IV or PO
Cytarabine
Intervention Type
DRUG
Given IV or PO
Dexamethasone
Intervention Type
DRUG
Given IV or PO
Etoposide
Intervention Type
DRUG
Given IV or PO
Ifosfamide
Intervention Type
DRUG
Given IV or PO
Laboratory Biomarker Analysis
Intervention Type
OTHER
Correlative studies
Placebo Administration
Intervention Type
OTHER
Given normal saline IV
Questionnaire Administration
Intervention Type
OTHER
Ancillary studies
Rituximab
Intervention Type
BIOLOGICAL
Given IV
Biospecimen Collection
Intervention Type
PROCEDURE
Undergo blood sample collection
Core Biopsy
Intervention Type
PROCEDURE
Undergo core needle biopsy
Bone Marrow Aspiration
Intervention Type
PROCEDURE
Undergo bone marrow aspiration and biopsy
Bone Marrow Biopsy
Intervention Type
PROCEDURE
Undergo bone marrow aspiration and biopsy
Echocardiography
Intervention Type
PROCEDURE
Undergo ECHO
Positron Emission Tomography
Intervention Type
PROCEDURE
Undergo PET/CT
Magnetic Resonance Imaging
Intervention Type
PROCEDURE
Undergo MRI
Computed Tomography
Intervention Type
PROCEDURE
Undergo PET/CT
Arm C (ascorbic acid and combination chemotherapy)
Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19. Patients also receive ifosfamide, carboplatin, and etoposide IV or PO, or cisplatin, cytarabine, and dexamethasone IV or PO, or gemcitabine hydrochloride, dexamethasone, and cisplatin IV or PO, or gemcitabine hydrochloride and oxaliplatin IV or PO, or oxaliplatin, cytarabine, and dexamethasone IV or PO according to standard regimen schedule. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve MR or SD after 2 cycles may switch to an alternative chemotherapy regimen. Patients additionally, undergo blood sample collection, core needle biopsy, bone marrow aspiration and biopsy, ECHO, PET/CT or MRI throughout study.
Group Type
EXPERIMENTAL
Ascorbic Acid
Intervention Type
DIETARY_SUPPLEMENT
Given IV
Carboplatin
Intervention Type
DRUG
Given IV or PO
Cisplatin
Intervention Type
DRUG
Given IV or PO
Cytarabine
Intervention Type
DRUG
Given IV or PO
Dexamethasone
Intervention Type
DRUG
Given IV or PO
Etoposide
Intervention Type
DRUG
Given IV or PO
Gemcitabine Hydrochloride
Intervention Type
DRUG
Given IV or PO
Ifosfamide
Intervention Type
DRUG
Given IV or PO
Laboratory Biomarker Analysis
Intervention Type
OTHER
Correlative studies
Oxaliplatin
Intervention Type
DRUG
Given IV or PO
Questionnaire Administration
Intervention Type
OTHER
Ancillary studies
Biospecimen Collection
Intervention Type
PROCEDURE
Undergo blood sample collection
Core Biopsy
Intervention Type
PROCEDURE
Undergo core needle biopsy
Bone Marrow Aspiration
Intervention Type
PROCEDURE
Undergo bone marrow aspiration and biopsy
Bone Marrow Biopsy
Intervention Type
PROCEDURE
Undergo bone marrow aspiration and biopsy
Echocardiography
Intervention Type
PROCEDURE
Undergo ECHO
Positron Emission Tomography
Intervention Type
PROCEDURE
Undergo PET/CT
Magnetic Resonance Imaging
Intervention Type
PROCEDURE
Undergo MRI
Computed Tomography
Intervention Type
PROCEDURE
Undergo PET/CT
Arm D (ascorbic acid)
Patients receive ascorbic acid IV TIW. Treatments repeat every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PICC or portacath placement prior to starting treatment, blood sample collection, bone marrow aspiration and biopsy throughout study.
Group Type
EXPERIMENTAL
Ascorbic Acid
Intervention Type
DIETARY_SUPPLEMENT
Given IV
Laboratory Biomarker Analysis
Intervention Type
OTHER
Correlative studies
Questionnaire Administration
Intervention Type
OTHER
Ancillary studies
Biospecimen Collection
Intervention Type
PROCEDURE
Undergo blood sample collection
Bone Marrow Aspiration
Intervention Type
PROCEDURE
Undergo bone marrow aspiration and biopsy
Bone Marrow Biopsy
Intervention Type
PROCEDURE
Undergo bone marrow aspiration and biopsy
Central Venous Cannula Insertion
Intervention Type
PROCEDURE
Undergo PICC placement
Portacath Placement
Intervention Type
PROCEDURE
Undergo portacath placement
ARM E (ascorbic acid, decitabine)
Patients receive ascorbic acid IV on days 1, 3 and 5 and decitabine IV over 1 hour on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 12 cycles may continue decitabine with or without ascorbic acid as long as clinically appropriate. Patients may also take vitamin C PO on days 6-28. Patients undergo PICC or portacath placement prior to starting treatment, blood sample collection, bone marrow aspiration and biopsy throughout study.
Group Type
EXPERIMENTAL
Ascorbic Acid
Intervention Type
DIETARY_SUPPLEMENT
Given IV
Decitabine
Intervention Type
DRUG
Given IV
Biospecimen Collection
Intervention Type
PROCEDURE
Undergo blood sample collection
Bone Marrow Aspiration
Intervention Type
PROCEDURE
Undergo bone marrow aspiration and biopsy
Bone Marrow Biopsy
Intervention Type
PROCEDURE
Undergo bone marrow aspiration and biopsy
Central Venous Cannula Insertion
Intervention Type
PROCEDURE
Undergo PICC placement
Portacath Placement
Intervention Type
PROCEDURE
Undergo portacath placement
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ascorbic Acid
Given IV
Intervention Type
DIETARY_SUPPLEMENT
Carboplatin
Given IV or PO
Intervention Type
DRUG
Cisplatin
Given IV or PO
Intervention Type
DRUG
Cytarabine
Given IV or PO
Intervention Type
DRUG
Dexamethasone
Given IV or PO
Intervention Type
DRUG
Etoposide
Given IV or PO
Intervention Type
DRUG
Gemcitabine Hydrochloride
Given IV or PO
Intervention Type
DRUG
Ifosfamide
Given IV or PO
Intervention Type
DRUG
Laboratory Biomarker Analysis
Correlative studies
Intervention Type
OTHER
Oxaliplatin
Given IV or PO
Intervention Type
DRUG
Placebo Administration
Given normal saline IV
Intervention Type
OTHER
Questionnaire Administration
Ancillary studies
Intervention Type
OTHER
Rituximab
Given IV
Intervention Type
BIOLOGICAL
Decitabine
Given IV
Intervention Type
DRUG
Biospecimen Collection
Undergo blood sample collection
Intervention Type
PROCEDURE
Core Biopsy
Undergo core needle biopsy
Intervention Type
PROCEDURE
Bone Marrow Aspiration
Undergo bone marrow aspiration and biopsy
Intervention Type
PROCEDURE
Bone Marrow Biopsy
Undergo bone marrow aspiration and biopsy
Intervention Type
PROCEDURE
Echocardiography
Undergo ECHO
Intervention Type
PROCEDURE
Positron Emission Tomography
Undergo PET/CT
Intervention Type
PROCEDURE
Magnetic Resonance Imaging
Undergo MRI
Intervention Type
PROCEDURE
Central Venous Cannula Insertion
Undergo PICC placement
Intervention Type
PROCEDURE
Portacath Placement
Undergo portacath placement
Intervention Type
PROCEDURE
Computed Tomography
Undergo PET/CT
Intervention Type
PROCEDURE
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
2-(1,2-dihydroxyethyl)-4,5-dihydroxy-furan-3-one
Asorbicap
C Vitamin
C-Long
Ce-Vi-Sol
Cecon
Cenolate
Cetane
Cevalin
L-Ascorbic Acid
VIT C
Vitamin C
Vitamin-C
Blastocarb
Carboplat
Carboplatin Hexal
Carboplatino
Carboplatinum
Carbosin
Carbosol
Carbotec
CBDCA
Displata
Ercar
JM-8
Nealorin
Novoplatinum
Paraplatin
Paraplatin AQ
Paraplatine
Platinwas
Ribocarbo
JM8
Abiplatin
Blastolem
Briplatin
CDDP
Cis-diammine-dichloroplatinum
Cis-diamminedichloridoplatinum
Cis-diamminedichloro Platinum (II)
Cis-diamminedichloroplatinum
Cis-dichloroammine Platinum (II)
Cis-platinous Diamine Dichloride
Cis-platinum
Cis-platinum II
Cis-platinum II Diamine Dichloride
Cismaplat
Cisplatina
Cisplatinum
Cisplatyl
Citoplatino
Citosin
Cysplatyna
DDP
Lederplatin
Metaplatin
Neoplatin
Peyrone's Chloride
Peyrone's Salt
Placis
Plastistil
Platamine
Platiblastin
Platiblastin-S
Platinex
Platinol
Platinol- AQ
Platinol-AQ
Platinol-AQ VHA Plus
Platinoxan
Platinum
Platinum Diamminodichloride
Platiran
Platistin
Platosin
.beta.-Cytosine arabinoside
1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-.beta.-D-Arabinofuranosylcytosine
1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-Beta-D-arabinofuranosylcytosine
1.beta.-D-Arabinofuranosylcytosine
2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-
2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-
Alexan
Ara-C
ARA-cell
Arabine
Arabinofuranosylcytosine
Arabinosylcytosine
Aracytidine
Aracytin
Aracytine
Beta-Cytosine Arabinoside
CHX-3311
Cytarabinum
Cytarbel
Cytosar
Cytosine Arabinoside
Cytosine-.beta.-arabinoside
Cytosine-beta-arabinoside
Erpalfa
Starasid
Tarabine PFS
U 19920
U-19920
Udicil
WR-28453
Aacidexam
Adexone
Aknichthol Dexa
Alba-Dex
Alin
Alin Depot
Alin Oftalmico
Amplidermis
Anemul mono
Auricularum
Auxiloson
Baycadron
Baycuten
Baycuten N
Cortidexason
Cortisumman
Decacort
Decadrol
Decadron
Decadron DP
Decalix
Decameth
Decasone R.p.
Dectancyl
Dekacort
Deltafluorene
Deronil
Desamethasone
Desameton
Dexa-Mamallet
Dexa-Rhinosan
Dexa-Scheroson
Dexa-sine
Dexacortal
Dexacortin
Dexafarma
Dexafluorene
Dexalocal
Dexamecortin
Dexameth
Dexamethasone Intensol
Dexamethasonum
Dexamonozon
Dexapos
Dexinoral
Dexone
Dinormon
Dxevo
Fluorodelta
Fortecortin
Gammacorten
Hemady
Hexadecadrol
Hexadrol
Lokalison-F
Loverine
Methylfluorprednisolone
Millicorten
Mymethasone
Orgadrone
Spersadex
TaperDex
Visumetazone
ZoDex
Demethyl Epipodophyllotoxin Ethylidine Glucoside
EPEG
Lastet
Toposar
Vepesid
VP 16
VP 16-213
VP 16213
VP-16-213
VP16
VP-16
dFdCyd
Difluorodeoxycytidine Hydrochloride
Gemcitabine HCI
Gemzar
LY-188011
LY188011
Asta Z 4942
Asta Z-4942
Cyfos
Holoxan
Holoxane
Ifex
IFO
IFO-Cell
Ifolem
Ifomida
Ifomide
Ifosfamidum
Ifoxan
IFX
Iphosphamid
Iphosphamide
Iso-Endoxan
Isoendoxan
Isophosphamide
Mitoxana
MJF 9325
MJF-9325
Naxamide
Seromida
Tronoxal
Z 4942
Z-4942
1-OHP
Ai Heng
Aiheng
Dacotin
Dacplat
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatine
JM-83
Oxalatoplatin
Oxalatoplatinum
RP 54780
RP-54780
SR-96669
ABP 798
BI 695500
C2B8 Monoclonal Antibody
Chimeric Anti-CD20 Antibody
CT-P10
IDEC-102
IDEC-C2B8
IDEC-C2B8 Monoclonal Antibody
MabThera
Monoclonal Antibody IDEC-C2B8
PF-05280586
Riabni
Rituxan
Rituximab ABBS
Rituximab ARRX
Rituximab Biosimilar ABP 798
Rituximab Biosimilar BI 695500
Rituximab Biosimilar CT-P10
Rituximab Biosimilar GB241
Rituximab Biosimilar IBI301
Rituximab Biosimilar JHL1101
Rituximab Biosimilar PF-05280586
Rituximab Biosimilar RTXM83
Rituximab Biosimilar SAIT101
Rituximab Biosimilar SIBP-02
rituximab biosimilar TQB2303
Rituximab PVVR
Rituximab-abbs
Rituximab-arrx
Rituximab-pvvr
RTXM83
Ruxience
Truxima
Ikgdar
Mabtas
Dacogen
Decitabine for Injection
Deoxyazacytidine
Dezocitidine
Biological Sample Collection
Biospecimen Collected
Specimen Collection
BIOPSY, CORE
CORE CNB
Core Needle
Core Needle Biopsy
Needle Biopsy
Biopsy of Bone Marrow
Biopsy, Bone Marrow
EC
ECHO
Medical Imaging, Positron Emission Tomography
PET
PET Scan
Positron emission tomography (procedure)
positron emission tomography scan
Positron-Emission Tomography
proton magnetic resonance spectroscopic imaging
PT
Magnetic Resonance
Magnetic Resonance Imaging (MRI)
Magnetic resonance imaging (procedure)
Magnetic Resonance Imaging Scan
Medical Imaging
Magnetic Resonance / Nuclear Magnetic Resonance
MR
MR Imaging
MRI
MRI Scan
MRIs
NMR Imaging
NMRI
nuclear magnetic resonance imaging
Structural MRI
sMRI
Central venous catheter
Central Venous Catheter Placement
Port-a-cath Placement
CAT
CAT Scan
Computed Axial Tomography
Computerized Axial Tomography
Computerized axial tomography (procedure)
Computerized Tomography
Computerized Tomography (CT) scan
CT
CT SCAN
tomography
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \>= 18 years
* Biopsy-proven relapsed or refractory lymphomas; relapsed is defined as a relapse that occurred after having a response to the last therapy that lasted \> 6 months; refractory is no response or relapse within 6 months; previous biopsies \< 6 months prior to treatment on this protocol will be acceptable
* NOTE: Arms A/B - relapsed or refractory DLBCL within 24 months from the end of anthracycline-based therapy; no prior salvage therapy; patients can have received radiation therapy as part of initial treatment but not specifically for relapse
* NOTE: Arm C patients include relapsed or refractory lymphoma patients of any type for which the recommended treatment includes one of the platinum-based regimens; of note, relapsed or refractory double-hit high grade lymphoma patients and relapsed or refractory Hodgkin lymphoma patients will be enrolled in Arm C; there is no limit on the number of prior therapies for Arm C patients; the patient must be eligible for a platinum-based regimen and must not have received the same regimen in the past without responding
* Measurable or assessable disease: measurable disease is defined as measurable by computed tomography (CT) \[dedicated CT or the CT portion of a positron emission tomography (PET)/CT\] or magnetic resonance imaging (MRI): to be considered measurable, there must be at least one lesion that has a single diameter of \>= 1.5 cm
* NOTE: Skin lesions can be used if the area is \>= 1.5 cm in at least one diameter and photographed with a ruler; patients with assessable disease by PET are also eligible as long as the assessable disease is biopsy proven lymphoma
* Arms A/B - eligible for treatment with ifosfamide, carboplatin, and etoposide (+/- rituximab)
* Arm C eligible for treatment with one of the following standard, every 3 week, platinum-based salvage regimens (with or without monoclonal antibody as appropriate for the disease):
* Ifosfamide/carboplatin/etoposide (ICE) or rituximab/ifosfamide/carboplatin/etoposide (RICE);
* Cisplatin, cytarabine (cytosine arabinoside), dexamethasone (DHAP) or RDHAP;
* Gemcitabine hydrochloride (gemcitabine), dexamethasone, cisplatin (GDP) or rituximab, gemcitabine, dexamethasone, cisplatin (RGDP);
* Gemcitabine and oxaliplatin (GemOx) or rituximab, gemcitabine and oxaliplatin (RGemOx);
* Oxaliplatin, cytosine arabinoside, dexamethasone (OAD) or rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD)
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
* Hemoglobin \>= 8.0 g/dL (may transfuse to meet this requirement), obtained =\< 14 days prior to registration
* Absolute neutrophil count (ANC) \>= 1500/mm\^3, obtained =\< 14 days prior to registration
* Platelet count \>= 75000/mm\^3, obtained =\< 14 days prior to registration
* Total bilirubin =\< 2 x upper limit of normal (ULN) (if \> 2 x ULN direct bilirubin is required and should be =\< 1.5 x ULN), obtained =\< 14 days prior to registration
* Alanine aminotransferase (ALT) and aspartate transaminase (AST) =\< 3 x ULN (=\< 5 x ULN for patients with liver involvement), obtained =\< 14 days prior to registration
* Creatinine =\< 1.6 mg/dL; if over 1.6 then the calculated creatinine clearance must be \>= 55 ml/min using the Cockcroft-Gault formula, obtained =\< 7 days prior to registration
* Negative pregnancy test done =\< 7 days prior to registration, for persons of childbearing potential only
* NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
* Human immunodeficiency virus (HIV) test done =\< 14 days prior to registration
* If positive, the CD4 count must be \> 400
* Provide written informed consent
* Willingness to have a central venous line \[peripherally inserted central catheter (PICC) or PORT\]
* Willingness to provide mandatory blood specimens for correlative research
* Willingness to provide mandatory tissue specimens for correlative research
* Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)
* Willingness to follow the requirements of the intravenous ascorbic acid program schedule
* ARM D: Patients who had a diagnosis of CCUS with one or more TET2 mutations or TET2 mutations with concurrent splicing genes mutations (SRSF2, U2AF1, SF3B1, and ZRSR2) or epigenetic regulator mutations (DNMT3A, EZH2, IDH1, IDH2). CCUS diagnosis being defined based on the absence of definitive morphologic evidence of hematologic neoplasms from bone marrow biopsy evaluation combined with evidence of pathogenic myeloid somatic mutation with a variant allele frequency (VAF) of at least 2% using our institution's next generation sequencing (NGS) panel (OncoHeme, Mayo Clinic)
* ARM D: ECOG performance status (PS) 0, 1 or 2
* ARM D: Patients must meet at least 1 of these 3 laboratory criteria to be enrolled:
* Hemoglobin =\< 10g/dL (obtained =\< 7 days prior to registration)
* Absolute neutrophil count (ANC) =\< 1000/mm\^3 (obtained =\< 7 days prior to registration)
* Platelet count =\< 100,000/mm\^ 3 (obtained =\< 7 days prior to registration)
* ARM D: Total bilirubin =\< 2 x ULN (if \> 2 x ULN direct bilirubin is required and should be =\< 1.5 x ULN) (obtained =\<7 days prior to registration)
* ARM D: Alanine aminotransferase (ALT) and aspartate transaminase (AST) =\< 3 x ULN (=\< 5 x ULN for patients with liver involvement) (obtained =\<7 days prior to registration)
* ARM D: Creatinine =\< 1.6 mg/dL (obtained =\<7 days prior to registration). If \> 1.6, then the Calculated creatinine clearance must be \>= 55 ml/min using the Cockcroft-Gault formula
* ARM D: Negative pregnancy test, for persons of childbearing potential only (obtained =\< 7 days prior to registration). NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
* ARM D: Provide written informed consent
* ARM D: Willingness to have a central venous line (PICC or PORT)
* ARM D: Willingness to provide mandatory blood specimens for correlative research
* ARM D: Willingness to return to enrolling institution (MCR) for follow-up (during the active monitoring phase of the study)
* ARM D: Willingness to follow the requirements of the intravenous ascorbic acid program schedule
* ARM E PRE-REGISTRATION: Age ≥ 18 years
* ARM E PRE-REGISTRATION: New or an established diagnosis of 2016 World Health Organization (WHO) defined chronic myelomonocytic leukemia with a somatic TET2, IDH1, or IDH2 mutation requiring treatment with DNA methyltransferase inhibitors/hypomethylating agents
* ARM E PRE-REGISTRATION: No prior CMML directed therapy.
* Exception: Received ≤ 1 cycle of azacitidine, decitabine, erythropoiesis stimulating agent therapy (ESA), or oral decitabine and cedazuridine. NOTE: Prior exposure to hydroxyurea is allowed. Continuation beyond the first cycle must be discussed with the principal investigator (PI)
* ARM E PRE-REGISTRATION: Creatinine ≤ 1.6 mg/dL. If \> 1.6, then the Calculated creatinine clearance must be ≥ 55 ml/min using the Cockcroft-Gault formula
* ARM E PRE-REGISTRATION: Willingness to provide mandatory research bone marrow sample for correlative research
* ARM E PRE-REGISTRATION: ECOG performance status (PS) 0, 1, or 2
* ARM E PRE-REGISTRATION: Provide written informed consent
* ARM E REGISTRATION: Willingness to provide mandatory blood specimens for correlative research
* ARM E REGISTRATION: Willingness to return to enrolling institution (MCR) for follow-up (during the active monitoring phase of the study)
* ARM E REGISTRATION: Recovered to grade 1 or baseline or established as sequelae from all toxic effects of previous therapy except alopecia
* ARM E REGISTRATION: Absolute neutrophil count (ANC) ≥ 500/mm\^3 (obtained ≤ 7 days prior to registration)
* ARM E REGISTRATION: Platelet count ≥ 20,000/mm\^3 (obtained ≤ 7 days prior to registration)
* ARM E REGISTRATION: Total bilirubin ≤ 1.5 x ULN ( ≤ 3 x ULN for patients with Gilbert's syndrome) (obtained ≤ 7 days prior to registration)
* ARM E REGISTRATION: Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 3 x ULN (obtained ≤ 7 days prior to registration)
* ARM E REGISTRATION: Ability to complete questionnaire by themselves or with assistance
* ARM E REGISTRATION: For a person of child-bearing potential (WOCBP): Must agree to use contraception or take measures to avoid pregnancy during the study. Adequate contraception is defined as follows:
* Complete true abstinence
* Consistent and correct use of one of the following methods of birth control:
* Male partner who is sterile prior to the female patient's entry into the study and is the sole sexual partner for that female patient
* Implants of levonorgestrel
* Injectable progestogen
* Intrauterine device (IUD) with a documented failure rate of less than 1% per year
* Oral contraceptive pill (either combined or progesterone only)
* Barrier method, for example: diaphragm with spermicide or condom with spermicide in combination with either implants of levonorgestrel or injectable progestogen
* ARM E REGISTRATION: WOCBP must have a negative serum or urine pregnancy test ≤ 7 days prior to registration. NOTE: WOCBP include any person who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea \> 12 consecutive months); or women on hormone replacement therapy with documented serum follicle stimulating hormone (FSH) level \> 35 mIU/mL. Even women who are using oral, implanted, or injectable contraceptive hormones or mechanical products such as an IUD or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy), must be considered to be of child-bearing potential. NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
* ARM E REGISTRATION: Persons who are able to father a child must use contraception during the study and for 3 months after the last treatment dose.
* Complete true abstinence
* Latex condom with a spermicidal agent
* Diaphragm with spermicide
* ARM E REGISTRATION: Willingness to have a central venous line (PICC or PORT)
* ARM E REGISTRATION: Willingness to follow the requirements of the intravenous ascorbic acid program schedule
* Biopsy-proven relapsed or refractory lymphomas; relapsed is defined as a relapse that occurred after having a response to the last therapy that lasted \> 6 months; refractory is no response or relapse within 6 months; previous biopsies \< 6 months prior to treatment on this protocol will be acceptable
* NOTE: Arms A/B - relapsed or refractory DLBCL within 24 months from the end of anthracycline-based therapy; no prior salvage therapy; patients can have received radiation therapy as part of initial treatment but not specifically for relapse
* NOTE: Arm C patients include relapsed or refractory lymphoma patients of any type for which the recommended treatment includes one of the platinum-based regimens; of note, relapsed or refractory double-hit high grade lymphoma patients and relapsed or refractory Hodgkin lymphoma patients will be enrolled in Arm C; there is no limit on the number of prior therapies for Arm C patients; the patient must be eligible for a platinum-based regimen and must not have received the same regimen in the past without responding
* Measurable or assessable disease: measurable disease is defined as measurable by computed tomography (CT) \[dedicated CT or the CT portion of a positron emission tomography (PET)/CT\] or magnetic resonance imaging (MRI): to be considered measurable, there must be at least one lesion that has a single diameter of \>= 1.5 cm
* NOTE: Skin lesions can be used if the area is \>= 1.5 cm in at least one diameter and photographed with a ruler; patients with assessable disease by PET are also eligible as long as the assessable disease is biopsy proven lymphoma
* Arms A/B - eligible for treatment with ifosfamide, carboplatin, and etoposide (+/- rituximab)
* Arm C eligible for treatment with one of the following standard, every 3 week, platinum-based salvage regimens (with or without monoclonal antibody as appropriate for the disease):
* Ifosfamide/carboplatin/etoposide (ICE) or rituximab/ifosfamide/carboplatin/etoposide (RICE);
* Cisplatin, cytarabine (cytosine arabinoside), dexamethasone (DHAP) or RDHAP;
* Gemcitabine hydrochloride (gemcitabine), dexamethasone, cisplatin (GDP) or rituximab, gemcitabine, dexamethasone, cisplatin (RGDP);
* Gemcitabine and oxaliplatin (GemOx) or rituximab, gemcitabine and oxaliplatin (RGemOx);
* Oxaliplatin, cytosine arabinoside, dexamethasone (OAD) or rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD)
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
* Hemoglobin \>= 8.0 g/dL (may transfuse to meet this requirement), obtained =\< 14 days prior to registration
* Absolute neutrophil count (ANC) \>= 1500/mm\^3, obtained =\< 14 days prior to registration
* Platelet count \>= 75000/mm\^3, obtained =\< 14 days prior to registration
* Total bilirubin =\< 2 x upper limit of normal (ULN) (if \> 2 x ULN direct bilirubin is required and should be =\< 1.5 x ULN), obtained =\< 14 days prior to registration
* Alanine aminotransferase (ALT) and aspartate transaminase (AST) =\< 3 x ULN (=\< 5 x ULN for patients with liver involvement), obtained =\< 14 days prior to registration
* Creatinine =\< 1.6 mg/dL; if over 1.6 then the calculated creatinine clearance must be \>= 55 ml/min using the Cockcroft-Gault formula, obtained =\< 7 days prior to registration
* Negative pregnancy test done =\< 7 days prior to registration, for persons of childbearing potential only
* NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
* Human immunodeficiency virus (HIV) test done =\< 14 days prior to registration
* If positive, the CD4 count must be \> 400
* Provide written informed consent
* Willingness to have a central venous line \[peripherally inserted central catheter (PICC) or PORT\]
* Willingness to provide mandatory blood specimens for correlative research
* Willingness to provide mandatory tissue specimens for correlative research
* Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)
* Willingness to follow the requirements of the intravenous ascorbic acid program schedule
* ARM D: Patients who had a diagnosis of CCUS with one or more TET2 mutations or TET2 mutations with concurrent splicing genes mutations (SRSF2, U2AF1, SF3B1, and ZRSR2) or epigenetic regulator mutations (DNMT3A, EZH2, IDH1, IDH2). CCUS diagnosis being defined based on the absence of definitive morphologic evidence of hematologic neoplasms from bone marrow biopsy evaluation combined with evidence of pathogenic myeloid somatic mutation with a variant allele frequency (VAF) of at least 2% using our institution's next generation sequencing (NGS) panel (OncoHeme, Mayo Clinic)
* ARM D: ECOG performance status (PS) 0, 1 or 2
* ARM D: Patients must meet at least 1 of these 3 laboratory criteria to be enrolled:
* Hemoglobin =\< 10g/dL (obtained =\< 7 days prior to registration)
* Absolute neutrophil count (ANC) =\< 1000/mm\^3 (obtained =\< 7 days prior to registration)
* Platelet count =\< 100,000/mm\^ 3 (obtained =\< 7 days prior to registration)
* ARM D: Total bilirubin =\< 2 x ULN (if \> 2 x ULN direct bilirubin is required and should be =\< 1.5 x ULN) (obtained =\<7 days prior to registration)
* ARM D: Alanine aminotransferase (ALT) and aspartate transaminase (AST) =\< 3 x ULN (=\< 5 x ULN for patients with liver involvement) (obtained =\<7 days prior to registration)
* ARM D: Creatinine =\< 1.6 mg/dL (obtained =\<7 days prior to registration). If \> 1.6, then the Calculated creatinine clearance must be \>= 55 ml/min using the Cockcroft-Gault formula
* ARM D: Negative pregnancy test, for persons of childbearing potential only (obtained =\< 7 days prior to registration). NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
* ARM D: Provide written informed consent
* ARM D: Willingness to have a central venous line (PICC or PORT)
* ARM D: Willingness to provide mandatory blood specimens for correlative research
* ARM D: Willingness to return to enrolling institution (MCR) for follow-up (during the active monitoring phase of the study)
* ARM D: Willingness to follow the requirements of the intravenous ascorbic acid program schedule
* ARM E PRE-REGISTRATION: Age ≥ 18 years
* ARM E PRE-REGISTRATION: New or an established diagnosis of 2016 World Health Organization (WHO) defined chronic myelomonocytic leukemia with a somatic TET2, IDH1, or IDH2 mutation requiring treatment with DNA methyltransferase inhibitors/hypomethylating agents
* ARM E PRE-REGISTRATION: No prior CMML directed therapy.
* Exception: Received ≤ 1 cycle of azacitidine, decitabine, erythropoiesis stimulating agent therapy (ESA), or oral decitabine and cedazuridine. NOTE: Prior exposure to hydroxyurea is allowed. Continuation beyond the first cycle must be discussed with the principal investigator (PI)
* ARM E PRE-REGISTRATION: Creatinine ≤ 1.6 mg/dL. If \> 1.6, then the Calculated creatinine clearance must be ≥ 55 ml/min using the Cockcroft-Gault formula
* ARM E PRE-REGISTRATION: Willingness to provide mandatory research bone marrow sample for correlative research
* ARM E PRE-REGISTRATION: ECOG performance status (PS) 0, 1, or 2
* ARM E PRE-REGISTRATION: Provide written informed consent
* ARM E REGISTRATION: Willingness to provide mandatory blood specimens for correlative research
* ARM E REGISTRATION: Willingness to return to enrolling institution (MCR) for follow-up (during the active monitoring phase of the study)
* ARM E REGISTRATION: Recovered to grade 1 or baseline or established as sequelae from all toxic effects of previous therapy except alopecia
* ARM E REGISTRATION: Absolute neutrophil count (ANC) ≥ 500/mm\^3 (obtained ≤ 7 days prior to registration)
* ARM E REGISTRATION: Platelet count ≥ 20,000/mm\^3 (obtained ≤ 7 days prior to registration)
* ARM E REGISTRATION: Total bilirubin ≤ 1.5 x ULN ( ≤ 3 x ULN for patients with Gilbert's syndrome) (obtained ≤ 7 days prior to registration)
* ARM E REGISTRATION: Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 3 x ULN (obtained ≤ 7 days prior to registration)
* ARM E REGISTRATION: Ability to complete questionnaire by themselves or with assistance
* ARM E REGISTRATION: For a person of child-bearing potential (WOCBP): Must agree to use contraception or take measures to avoid pregnancy during the study. Adequate contraception is defined as follows:
* Complete true abstinence
* Consistent and correct use of one of the following methods of birth control:
* Male partner who is sterile prior to the female patient's entry into the study and is the sole sexual partner for that female patient
* Implants of levonorgestrel
* Injectable progestogen
* Intrauterine device (IUD) with a documented failure rate of less than 1% per year
* Oral contraceptive pill (either combined or progesterone only)
* Barrier method, for example: diaphragm with spermicide or condom with spermicide in combination with either implants of levonorgestrel or injectable progestogen
* ARM E REGISTRATION: WOCBP must have a negative serum or urine pregnancy test ≤ 7 days prior to registration. NOTE: WOCBP include any person who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea \> 12 consecutive months); or women on hormone replacement therapy with documented serum follicle stimulating hormone (FSH) level \> 35 mIU/mL. Even women who are using oral, implanted, or injectable contraceptive hormones or mechanical products such as an IUD or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy), must be considered to be of child-bearing potential. NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
* ARM E REGISTRATION: Persons who are able to father a child must use contraception during the study and for 3 months after the last treatment dose.
* Complete true abstinence
* Latex condom with a spermicidal agent
* Diaphragm with spermicide
* ARM E REGISTRATION: Willingness to have a central venous line (PICC or PORT)
* ARM E REGISTRATION: Willingness to follow the requirements of the intravenous ascorbic acid program schedule
Exclusion Criteria
* Any of the following:
* Pregnant persons
* Nursing persons
* Persons of childbearing potential who are unwilling to employ adequate contraception
* Any therapy =\< 2 weeks prior to registration; NOTE: Exception: patients on ibrutinib or corticosteroids (any dose) may continue therapy up until the new regimen has started at investigator discretion; corticosteroids can be tapered to lowest possible dose after start of treatment at investigator discretion. Exception: Palliative radiation is allowed
* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, pulmonary congestion or pulmonary edema, clinical dehydration, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Receiving any other investigational agent which would be considered as a treatment for the lymphoma
* Other active malignancy than lymphoma
* NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer that could interfere with this protocol therapy; patients on hormonal therapy for treated breast or prostate cancer are permitted if they meet other eligibility criteria; patients with non-melanotic skin cancer may enroll
* History of myocardial infarction =\< 6 months, or current symptomatic congestive heart failure or left ventricular ejection fraction (LVEF) \< 40% or with \> grade 2 diastolic dysfunction, with no symptoms or signs of heart failure
* Known G6PD (glucose-6-phosphate dehydrogenase) deficiency (below lower limit of normal)
* Patients with active central nervous system (CNS) lymphoma or active cerebrospinal fluid (CSF) involvement with malignant cells requiring CNS-specific therapy with IV or intrathecal (IT) methotrexate (MTX); Note: Patients with any prior CNS lymphoma (parenchymal or leptomeningeal) MUST be in complete remission (CR) in those compartments without any maintenance therapy required
* Patients with uncontrolled or symptomatic kidney stones
* Known paroxysmal nocturnal hemoglobinuria (PNH)
* ARM D: Bona-fide hematological neoplasm
* ARM D: Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:
* Pregnant persons
* Nursing persons
* Persons of childbearing potential who are unwilling to employ adequate contraception
* ARM D: Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
* ARM D: Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, pulmonary congestion or pulmonary edema, clinical dehydration, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* ARM D: History of myocardial infarction =\< 6 months, or current symptomatic congestive heart failure or known LVEF \< 40% or with \> grade 2 diastolic dysfunction, with no symptoms or signs of heart failure
* ARM D: Patients with uncontrolled or symptomatic kidney stones
* ARM D: Known paroxysmal nocturnal hemoglobinuria (PNH)
* ARM D: Known G6PD (glucose-6-phosphate dehydrogenase) deficiency (below lower limit of normal)
* ARM E PRE-REGISTRATION: Myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) overlap syndromes other than CMML
* ARM E PRE-REGISTRATION: Active central nervous system disease
* ARM E PRE-REGISTRATION: Any active disease condition that would render the protocol treatment dangerous or impair the ability of the patient to receive study drug
* ARM E PRE-REGISTRATION: Concurrent active malignancy, except adequately treated nonmelanoma skin cancer. History of curatively treated in situ cancer of the cervix, curatively treated in situ cancer of the breast, or other solid tumors curatively treated is allowed as long as there is no evidence of disease for \> 2 years
* ARM E PRE-REGISTRATION: Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
* ARM E PRE-REGISTRATION: Disease requiring systemic treatment with systemic immunosuppression with steroid steroids at a dose of ≥ 20 mg/day prednisone (or equivalent). Exceptions: Intermittent use of bronchodilators or inhaled steroids, local steroid injections, topical steroids
* ARM E PRE-REGISTRATION: Patients with uncontrolled or symptomatic kidney stones
* ARM E REGISTRATION: New York Heart Association (NYHA) class III/IV heart failure or active angina/angina equivalents
* ARM E REGISTRATION: History of myocardial infarction ≤ 6 months, or current symptomatic congestive heart failure or known LVEF \< 40% or with \> grade 2 diastolic dysfunction, with no symptoms or signs of heart failure
* ARM E REGISTRATION: Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, clinically significant cardiac arrhythmia, unstable angina pectoris, clinically significant nonhealing or healing wounds, pulmonary congestion or pulmonary edema, significant pulmonary disease (shortness of breath at rest or mild exertion), uncontrolled infection, clinical dehydration, or psychiatric illness/social situations that would limit compliance with study requirements
* ARM E REGISTRATION: Known G6PD (glucose-6-phosphate dehydrogenase) deficiency (below lower limit of normal)
* ARM E REGISTRATION: Any of the following because this study involves an agent that has known genotoxic, mutagenic, and teratogenic effects:
* Pregnant persons
* Nursing persons
* Persons of childbearing potential who are unwilling to employ adequate contraception
* Pregnant persons
* Nursing persons
* Persons of childbearing potential who are unwilling to employ adequate contraception
* Any therapy =\< 2 weeks prior to registration; NOTE: Exception: patients on ibrutinib or corticosteroids (any dose) may continue therapy up until the new regimen has started at investigator discretion; corticosteroids can be tapered to lowest possible dose after start of treatment at investigator discretion. Exception: Palliative radiation is allowed
* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, pulmonary congestion or pulmonary edema, clinical dehydration, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Receiving any other investigational agent which would be considered as a treatment for the lymphoma
* Other active malignancy than lymphoma
* NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer that could interfere with this protocol therapy; patients on hormonal therapy for treated breast or prostate cancer are permitted if they meet other eligibility criteria; patients with non-melanotic skin cancer may enroll
* History of myocardial infarction =\< 6 months, or current symptomatic congestive heart failure or left ventricular ejection fraction (LVEF) \< 40% or with \> grade 2 diastolic dysfunction, with no symptoms or signs of heart failure
* Known G6PD (glucose-6-phosphate dehydrogenase) deficiency (below lower limit of normal)
* Patients with active central nervous system (CNS) lymphoma or active cerebrospinal fluid (CSF) involvement with malignant cells requiring CNS-specific therapy with IV or intrathecal (IT) methotrexate (MTX); Note: Patients with any prior CNS lymphoma (parenchymal or leptomeningeal) MUST be in complete remission (CR) in those compartments without any maintenance therapy required
* Patients with uncontrolled or symptomatic kidney stones
* Known paroxysmal nocturnal hemoglobinuria (PNH)
* ARM D: Bona-fide hematological neoplasm
* ARM D: Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:
* Pregnant persons
* Nursing persons
* Persons of childbearing potential who are unwilling to employ adequate contraception
* ARM D: Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
* ARM D: Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, pulmonary congestion or pulmonary edema, clinical dehydration, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* ARM D: History of myocardial infarction =\< 6 months, or current symptomatic congestive heart failure or known LVEF \< 40% or with \> grade 2 diastolic dysfunction, with no symptoms or signs of heart failure
* ARM D: Patients with uncontrolled or symptomatic kidney stones
* ARM D: Known paroxysmal nocturnal hemoglobinuria (PNH)
* ARM D: Known G6PD (glucose-6-phosphate dehydrogenase) deficiency (below lower limit of normal)
* ARM E PRE-REGISTRATION: Myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) overlap syndromes other than CMML
* ARM E PRE-REGISTRATION: Active central nervous system disease
* ARM E PRE-REGISTRATION: Any active disease condition that would render the protocol treatment dangerous or impair the ability of the patient to receive study drug
* ARM E PRE-REGISTRATION: Concurrent active malignancy, except adequately treated nonmelanoma skin cancer. History of curatively treated in situ cancer of the cervix, curatively treated in situ cancer of the breast, or other solid tumors curatively treated is allowed as long as there is no evidence of disease for \> 2 years
* ARM E PRE-REGISTRATION: Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
* ARM E PRE-REGISTRATION: Disease requiring systemic treatment with systemic immunosuppression with steroid steroids at a dose of ≥ 20 mg/day prednisone (or equivalent). Exceptions: Intermittent use of bronchodilators or inhaled steroids, local steroid injections, topical steroids
* ARM E PRE-REGISTRATION: Patients with uncontrolled or symptomatic kidney stones
* ARM E REGISTRATION: New York Heart Association (NYHA) class III/IV heart failure or active angina/angina equivalents
* ARM E REGISTRATION: History of myocardial infarction ≤ 6 months, or current symptomatic congestive heart failure or known LVEF \< 40% or with \> grade 2 diastolic dysfunction, with no symptoms or signs of heart failure
* ARM E REGISTRATION: Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, clinically significant cardiac arrhythmia, unstable angina pectoris, clinically significant nonhealing or healing wounds, pulmonary congestion or pulmonary edema, significant pulmonary disease (shortness of breath at rest or mild exertion), uncontrolled infection, clinical dehydration, or psychiatric illness/social situations that would limit compliance with study requirements
* ARM E REGISTRATION: Known G6PD (glucose-6-phosphate dehydrogenase) deficiency (below lower limit of normal)
* ARM E REGISTRATION: Any of the following because this study involves an agent that has known genotoxic, mutagenic, and teratogenic effects:
* Pregnant persons
* Nursing persons
* Persons of childbearing potential who are unwilling to employ adequate contraception
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Sponsor Role
collaborator
Mayo Clinic
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas E Witzig, M.D.
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic Health Systems-Mankato
Mankato, Minnesota, United States
Site Status
NOT_YET_RECRUITING
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Site Status
RECRUITING
Mayo Clinic Health System-Eau Claire Clinic
Eau Claire, Wisconsin, United States
Site Status
NOT_YET_RECRUITING
Mayo Clinic Health System-Franciscan Healthcare
La Crosse, Wisconsin, United States
Site Status
ACTIVE_NOT_RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Xie Z, Fernandez J, Lasho T, Finke C, Amundson M, McCullough KB, LaPlant BR, Mangaonkar AA, Gangat N, Reichard KK, Elliott M, Witzig TE, Patnaik MM. High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations. Blood. 2024 Dec 5;144(23):2456-2461. doi: 10.1182/blood.2024024962.
Reference Type
DERIVED
Related Links
Access external resources that provide additional context or updates about the study.
https://www.mayo.edu/research/clinical-trials
Mayo Clinic Clinical Trials
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2018-00057
Identifier Type: REGISTRY
Identifier Source: secondary_id
LS1781
Identifier Type: OTHER
Identifier Source: secondary_id
17-008096
Identifier Type: OTHER
Identifier Source: secondary_id
LS1781
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
NCT05418088
RECRUITING
PHASE1
Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL)
NCT00626444
TERMINATED
PHASE2
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
NCT04870944
RECRUITING
PHASE1/PHASE2
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
NCT00005803
COMPLETED
PHASE1/PHASE2
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
NCT00002494
COMPLETED
PHASE2
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
NCT02669017
COMPLETED
PHASE1
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
NCT00005977
COMPLETED
PHASE3
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia
NCT00275080
COMPLETED
PHASE1
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
NCT01658319
COMPLETED
PHASE1
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
NCT03259503
COMPLETED
PHASE1
High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma
NCT02531841
UNKNOWN
PHASE3
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
NCT04803201
SUSPENDED
PHASE2
Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases
NCT00357708
COMPLETED
PHASE1
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia
NCT00005786
TERMINATED
NA
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
NCT02153580
ACTIVE_NOT_RECRUITING
PHASE1
17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
NCT00089271
COMPLETED
PHASE1
Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT03518112
TERMINATED
PHASE2
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
NCT02109224
TERMINATED
PHASE1
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
NCT00006125
COMPLETED
PHASE2
A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
NCT02640833
WITHDRAWN
PHASE1
CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
NCT00290472
COMPLETED
PHASE2
Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL
NCT00074282
COMPLETED
PHASE2
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
NCT02393157
RECRUITING
PHASE2
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
NCT04220008
WITHDRAWN
PHASE2
Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment
NCT00436618
COMPLETED
PHASE2